% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schilbach:21472,
      author       = {Schilbach, L. and Weiss, P.H. and Kuhn, J. and Timmermann,
                      L. and Klosterkötter, J. and Huff, W.},
      title        = {{P}harmacological treatment of deep brain
                      stimulation-induced hypomania leads to clinical remission
                      while preserving motor benefits.},
      journal      = {Neurocase},
      volume       = {18},
      issn         = {1355-4794},
      address      = {London [u.a.]},
      publisher    = {Psychology Press},
      reportid     = {PreJuSER-21472},
      pages        = {152 - 159},
      year         = {2012},
      note         = {Record converted from VDB: 12.11.2012},
      abstract     = {Deep brain stimulation (DBS) of the subthalamic nucleus
                      (STN) is an effective treatment for Parkinson's disease, but
                      can lead to adverse effects including psychiatric
                      disturbance. Little is known about the risk factors and
                      treatment options for such effects. Here, we describe a
                      patient who reproducibly developed stimulation-induced
                      hypomania when using ventrally located electrodes and
                      responded well to pharmacological intervention while leaving
                      the stimulation parameters unchanged to preserve motor
                      benefits. In spite of clinical remission,
                      [¹⁵O]-positron-emission-tomography (PET) demonstrated
                      activation patterns similar to those reported during mania.
                      This case, therefore, highlights an important treatment
                      option of adverse effects of DBS, but also points toward the
                      need for investigations of its risk factors and their
                      underlying neurobiological mechanisms.},
      keywords     = {Antimanic Agents: therapeutic use / Bipolar Disorder: drug
                      therapy / Bipolar Disorder: etiology / Clozapine:
                      therapeutic use / Deep Brain Stimulation: adverse effects /
                      Humans / Male / Middle Aged / Parkinson Disease: therapy /
                      Treatment Outcome / Valproic Acid: therapeutic use /
                      Antimanic Agents (NLM Chemicals) / Clozapine (NLM Chemicals)
                      / Valproic Acid (NLM Chemicals) / J (WoSType)},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {Funktion und Dysfunktion des Nervensystems (FUEK409) /
                      89572 - (Dys-)function and Plasticity (POF2-89572)},
      pid          = {G:(DE-Juel1)FUEK409 / G:(DE-HGF)POF2-89572},
      shelfmark    = {Clinical Neurology / Psychiatry / Psychology},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:21919560},
      UT           = {WOS:000302400900009},
      doi          = {10.1080/13554794.2011.568502},
      url          = {https://juser.fz-juelich.de/record/21472},
}